VANCOUVER, British Columbia, Jan. 17, 2023 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end Canadian-based drug manufacturer and formulator licensed by Health Canada to produce and supply natural, GMP grade psilocybin, synthetic psychedelic substances, most notably MDMA, and high-quality functional mushrooms…

Source

Previous articleAlgernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study
Next articlePsychedelics 2022: A Year in Review